PGP and cancer: Tenacissimoside A has been reported to reverses MDR in P-gp overexpressing cancer cells (HepG2/Dox cells) toward doxorubicin, vinblastine, puromycin and paclitaxel via direct interaction with P-gp substrate site [210].